Plaque Psoriasis

Catch up on news headlines highlighted in the dermatology space by HCPLive in 2025 with this Year in Review.

Catch up on some of the most notable headlines in psoriasis news coverage from 2025 with our Year in Review.

In this analysis, investigators assessed the effects of any weight-loss intervention, behavioural or pharmacological, on the severity of psoriasis as well as quality-of-life outcomes.

The highly selective oral TYK2 inhibitor met coprimary endpoints for sPGA 0/1 and PASI 75 at week 16 versus placebo in the phase 3 Latitude studies.

Investigators highlighted patterns of addictive behavior among those with chronic skin diseases in European tertiary dermatology centers.

Vanda Pharmaceuticals submitted a BLA to the FDA for imsidolimab, a novel IgG4 IL-36 receptor antagonist, to treat generalized pustular psoriasis (GPP).

The phase 3 DISCREET study explored the safety and efficacy of apremilast in treating patients with moderate to severe genital psoriasis over 32 weeks.

From diagnosis, investigators sought to explore psoriasis characteristics, patient demographics, patterns of treatment, and disease progression.

Explore the evolving role of AI in dermatology, balancing its benefits with concerns over accuracy, bias, and the human touch in patient care.

This analysis suggests a potential causal association between psoriasis and depression, highlighting the need for mental health screening in patients with psoriasis.

This systematic review and meta-analysis looked at research on the efficacy and safety of topical roflumilast 0.3% in patients with plaque psoriasis.

This review of November 2025 highlights several notable news stories covered in the dermatology space.

In this analysis, investigators explored potential impacts of antibiotic exposure on the persistence of biologic treatments in patients living with psoriasis.

This global analysis highlights the incidence of psoriasis around the world by 2025, noting various distinctions in region, age groups, and sex.

The Psoriasis Study of Health Outcomes (PSoHO) was designed as a 36-month, non-interventional, international cohort study of patients with psoriasis.

The FDA acceptance of Arcutis's supplemental New Drug Application (sNDA) was announced for roflumilast cream 0.3% (Zoryve).

In a session presented at the SDPA Fall Conference, Karan Lal, DO, spoke on the topic of GLP-1 agonist drugs for weight loss and their connection to dermatology.

Panelists discuss how including adolescent patients (12 years and older) from the outset of phase 3 studies provides immediate treatment options for younger patients and increases clinician confidence in prescribing to this population.

Panelists discuss how icotrokinra demonstrated significant efficacy in high-impact areas, achieving clear or almost clear scalp in 66% of patients and clear or almost clear genital psoriasis in 77% of patients at week 16.

At the 2025 SDPA Fall Conference, Laura Bush, DMSc, PA-C, presented the next iteration of an IMID and Obesity bootcamp session.

In this review of the month of October, HCPLive highlights some of the most significant dermatology news updates.

In his Fall Clinical interview, Chovatiya highlights several key takeaways from his talk on generalized pustular psoriasis (GPP) management.

These phase 4 data from the UnlIMMited trial highlight the efficacy and safety of risankizumab for psoriasis in the genital or scalp region.

Panelists discuss how the durability data through week 52 show nearly 90% of adult patients and over 90% of adolescent patients maintaining PASI 75 response, addressing patient concerns about long-term treatment effectiveness.

Panelists discuss how the ICONIC-LEAD placebo-controlled studies showed icotrokinra achieving clear or almost clear skin in about 75% of patients at week 24, representing unprecedented efficacy for an oral psoriasis therapy.